High rates of SARS-CoV-2 reinfection in residents of long term care facilities despite robust spike-specific immunity following serial vaccination Authors: Gokhan Tut, Tara Lancaster, Panagiota Sylla, David Bone, Christopher Bentley, Azar Jadir, Rachel Bruton, Katie Spencer, Soumyajit Mallick, Ahmed Elzaidi, Alexander Dowell, Mary Wu, Ruth Harvey, Edward Carr, Rupert Beale, Maria Krutikov, Oliver Stirrup, Borscha Azmi, Andrew Hayward, Andrew Copas, Laura Shallcross, Paul Moss, Crick COVID Immunity Pipeline, Dhammika Leshan Wannigama, Mohammad Rashidul Hashan, Mohammad Rashidul Hashan, Mohammad Rashidul Hashan Published: 2026 ABSTRACT Older adult residents of long-term care facilities (LTCFs) suffered high rates of mortality during the initial stages of the COVID-19 pandemic but their clinical risk has decreased markedly following vaccination. Here we determined humoral and cellular immunity following delivery of a 5th vaccine dose, an mRNA spike B1:BA.1 bivalent vaccine, to care home residents. The delivery of a 5th vaccine elicited a plateau of spike-specific immunity that remained broadly stable over 100 days in almost all people. Despite this, 15% of residents had a primary infection and 30% became reinfected during 6-months of follow up. These findings reveal that serial vaccine delivery can establish robust systemic spike-specific immune responses in frail older people but that this does not reliably prevent SARS-CoV-2 reinfection. As such, additional approaches should be considered to reduce reinfection risk in this vulnerable population group. Introduction Age and frailty are important determinants of the clinical severity of COVID-19. Residents living in long-term care facilities (LTCFs) were at particular risk, with high rates of mortality observed prior to the introduction of SARS-CoV-2 vaccines. Vaccination provided strong clinical protection in this group although immune responses following primary series vaccination were suboptimal and required enhancement through booster doses [1]. Furthermore, although vaccination attenuated the clinical burden of infection, the infection-related mortality rate remained elevated in large national studies in 2023 [2,3] although more reassuring outcomes have been observed in other settings. In particular, the increased infection prevalence in Italian nursing homes following evolution of the Omicron variant was not associated with increased mortality rate [4] and a 4th vaccine dose provided protection against mortality in Sweden [5]. The emergence of the Omicron SARS-CoV-2 variant led to the deployment of bivalent or Omicron-specific vaccines which have demonstrated encouraging Omicron-specific immunogenicity in a range of studies, including the LTCF setting [6]. Nevertheless, detailed assessments of immunogenicity in such vulnerable populations remain limited and have not been related to risk of subsequent infection or reinfection over the study period [7]. This information is of value both to assess the justification for continuation of the vaccination programme as well as assessing if such a programme alone is sufficient to minimise reinfection rates. We determined adaptive immune responses against spike protein following bivalent vaccination in the LTCF setting. Delivery of 5 vaccines was seen to provide a stable immune platform of antibody and cellular responses against several Omicron variants, largely independent of prior infection status. Despite this, infection rates remain high and indicate a potential need for additional protective approaches. Materials and methods Sample collection The VIVALDI study (ISRCTN14447421) is a prospective cohort study which was set up to investigate SARS-CoV-2 transmission, infection outcomes and immunity in residents and staff in LTCFs in England that provide residential and/or nursing care for adults aged 65 years and over (https://wellcomeopenresearch.org/articles/5-232/v2). LTCFs were identified by the Senior Management Team, or by the National Institute for Health and Care Research (NIHR) Clinical Research Network. Pseudonymised clinical (vaccination status, PCR/LFD test results, hospitalisation, death) and demographic (age, sex, staff member versus resident) data were retrieved for staff and residents from participating LTCFs through national surveillance systems. All participants provided written informed consent for blood sample collection or if residents lacked the capacity to consent, a personal or nominated consultee was identified to act on their behalf. Blood sampling was carried out from 27th July 2022 until 19th of January 2023, aligning with the administration of the bivalent vaccine. Ethical approval for this study was obtained from the South Central – Hampshire B Research Ethics Committee, REC Ref: 20/SC/0238. Data linkage Roche anti-nucleocapsid antibody test results were submitted to the COVID-19 datastore (https://data.england.nhs.uk/covid-19/), pseudonymised and linked to routinely held data on age, sex, LTCF, role (staff or resident), and results of PCR or lateral flow device (LFD) SARS-CoV-2 testing performed through the national SARS-CoV-2 testing programme (REF). Using the common pseudo-identifier based on the individuals’ NHS number, linkage was undertaken to vaccination status (date and vaccine type) derived from the National Immunisations Management System (NIMS) and dates and diagnostic codes for hospitalisations recorded in the Hospital Episode Statistics (HES) dataset as well as for any deaths from the Office for National Statistics (ONS) dataset. Individual-level records were further linked to each LTCF using the unique Care Quality Commission location ID (CQC-ID) recorded on PCR/LFD tests, allocated by the Care Quality Commission who regulate all providers of health and social care in the UK. The legal basis for accessing data without consent was initially under the Control of Patient Information Regulations 2002 (notice in place between March 2020 and June 2022). The study obtained section 251 support from the Health Research Authority’s Confidentiality Advisory Group (CAG) (ref 21/CAG/0156) in March 2022. Inclusion criteria Staff and residents were eligible for inclusion if samples could be linked to a pseudo-identifier enabling data linkage. We included samples from participants that had received a primary vaccine course of two doses, with or without a third, fourth and fifth dose. Fourth and fifth dose administration coincided with the introduction of the bivalent vaccine. Samples obtained within 6 days of booster vaccine were excluded to ensure peak immune responses were reached. Due to limited PCR testing up to July 2020 and after March 2022 it was not possible to determine when individuals had been infected with SARS-CoV-2 based on PCR/LFD alone. Past infection with SARS-CoV-2 was defined based on results of MSD nucleocapsid antibody test and Abbotts test using thresholds and methods outlined below. No statistical methods were used to pre-determine sample size but participant numbers are similar to those reported in previous publications [8–11]. 298 participants (141 residents and 157 staff) received a third vaccine. Median time between administration of the third vaccine dose was 333 days for residents (IQR 285−401) and 363 days for staff (IQR 328−408). Out of the 298 recipients of three COVID-19 vaccine doses, 5 residents and 45 staff did not receive further doses of COVID-19 vaccine. A total of 195 participants (135 residents and 60 staff) received a 4th dose of COVID-19 vaccine. The median time between the 4th vaccine and sample collection was 63 days for staff (IQR 41–99) and 133 days for residents (IQR 106–205). 67 participants (22%) received a 5th dose of COVID-19 vaccine consisting of 64 residents and 3 staff members, The median time to sample collection was 30 days for staff (IQR 26–67) and 65 days for residents (IQR 31–104). Out of 141 LTCF residents, 30 provided matched samples, once after administration of a 4th dose of COVID-19 vaccine and once after receiving a 5th dose of COVID-19 vaccine. Sample preparation Anticoagulated blood samples were processed within 24 hours and PBMC isolated using SepMate (Stemcell) density centrifugation tube and rested overnight in R10 (RPMI + 10% FBS + Pen/Strep) media at 37°C in 5% CO2. Plasma and serum samples were assessed antibody binding and viral neutralisation. Serological analysis of SARS-CoV-2-specific immune response Quantitative IgG antibody titres were measured against Spike (S) and Nucleocapsid (N) proteins using the MSD V-PLEX COVID-19 IgG Kit (SARS-CoV-2 Panel 2, 25 and 27) (Lot number K0081795) in line with prior reports [1]. Past infection with SARS-CoV-2 was defined by a Nucleocapsid (N) IgG titre of 1200 AU/ml. Data was generated by Methodical Mind software and analysed with MSD Discovery Workbench (v4.0) software. Presented data were adjusted for any sample dilutions. Quantification of SARS-CoV-2-specific cellular responses Pepmixes pool containing 15-mer peptides overlapping by 10aa from either SARS-CoV-2 Wuhan or Omicron BA.1 or BA4/5 Spike S1 were purchased from JPT Peptide Technologies (Germany). ELISpot analysis was used to assess T cell responses with the IFN/IL-2 FluoroSpot Plus Kit (Mabtech, Sweden). 2-3x105 PBMC were used in assays as previously described [1]. Cytokine concentrations within ELISpot supernatants were assayed using a LEGENDplex™ COVID-19 Cytokine Storm Panel 1 (BioLegend, Lot Number B332349) and analysed using the LEGENDplex™ Data Analysis Software Suite (BioLegend). High-throughput live virus microneutralisation assay The B.1.617.2 (“Delta”) isolate was MS066352H (GISAID accession number EPI_ISL_1731019), and was kindly provided by Prof. Wendy Barclay, Imperial College London, London, UK through the Genotype-to-Phenotype National Virology Consortium (G2P-UK). The BA.1 (“Omicron”) isolate was M21021166, and was kindly provided by Prof. Gavin Screaton, University of Oxford, Oxford, UK through the Genotype-to-Phenotype National Virology Consortium (G2P-UK). Viral isolates were propagated in Vero V1 cells. Briefly, 50% confluent monolayers of Vero V1 cells were infected with the given SARS CoV-2 strains at an MOI of approx. 0.001. Cells were washed once with DMEM (Sigma; D6429), then 5 ml virus inoculum made up in DMEM was added to each T175 flask and incubated at room temperature for 30 minutes. DMEM + 1% FCS (Biosera; FB-1001/500) was added to each flask. Cells were incubated at 37° C, 5% CO2 for 4 days until extensive cytopathogenic effect was observed. Supernatant was harvested and clarified by centrifugation at 2000 rpm for 10 minutes in a benchtop centrifuge. Supernatant was aliquoted and frozen at −80°C. Full protocol for variant virus culture and microneutralization assay available from Wu et al. 2022 [12]. High-throughput live virus microneutralisation assay was run as previously described [13]. Specifically, VERO E6 cells (Institut Pasteur) at 90−100% confluency in 384-well plates (Greiner) were infected with SARS-CoV-2 variants at an MOI of <1 in the presence of patient serum samples in serial dilutions. Cells were fixed with 4% final formaldehyde, blocked and permeabilised with 3% BSA + 0.2% TritonX-100 in PBS (v/v), and infected cells stained using a Biotin-CR3009 antibody (produced in-house), which specifically detects SARS-CoV-2 N-protein, and Streptavidin-Alexa488 (Invitrogen). Cellular DNA detected using DAPI. An Opera Phenix (Perkin Elmer) automated microscope was used to image whole wells at 5x and the fluorescent areas calculated using the Phenix-associated software Harmony (Perkin Elmer). The sample IC50 against a variant was estimated by fitting a 4-parameter dose response curve using SciPy and reported as the fold-dilution of serum samples required to inhibit 50% of detected infection, with additional annotation if the result lies outside the quantitative range (complete inhibition, no inhibition, weak inhibition). Statistical analysis All data were checked for normality using the Kolmogorov-Smirnov test. For comparative analysis of 2 groups a Mann Whitney test was applied. For paired data, 2-tailed paired t-tests (parametric) or Wilcoxon matched-pairs signed rank tests (non-parametric) were applied. For comparative analysis with 3 or more groups a Kruskal-Wallis test was used, and for multiple comparisons uncorrected Dunn’s test was used for non-parametric data. Spearman’s rank correlation coefficients were calculated and tested for correlations. P values <0.05 were considered to be statistically significant. In Fig 1, matched samples were collected at significantly different intervals following the fourth and fifth vaccine doses. To assess whether equivalent post-vaccination sampling windows were compared between the fourth and fifth vaccine doses, the number of days between vaccination and sample collection was calculated for each sample. For samples assigned to the Early_4 and Late_4 cohorts, days post-vaccination were calculated relative to the fourth vaccine dose. For samples assigned to the Ealy_5 and Late_5 cohorts, days post-vaccination were calculated relative to the fifth vaccine dose. Sample intervals were compared between the Early_4 and Early_5 cohorts and between the Late_4 and Late_5 cohorts using the paired Wilcoxon signed-rank Test. Spike-specific antibody titres plateau after 5 vaccines and remain stable over 100 days in LTCF residents. (A) Spike-specific antibody titre following the fourth and fifth SARS-CoV-2 vaccine doses in non-prior-infected long-term care facility (LTCF) residents. Antibody responses were analysed using a linear mixed-effects model with participants included as a random effect. Tukey-adjusted pairwise comparisons identified no significant differences between time points (Early_4 vs Late_4, p = 0.9931; Early_4 vs Early_5, p = 0.9308; Early_4 vs Late_5, p = 0.9999; Late_4 vs Early_5, p = 0.9541; Late_4 vs Late_5, p = 0.9229; Early_5 vs Late_5, p = 0.8496). Data are shown as box-and-whiskers plots, where the centre line represents the median, the box represents the interquartile range (IQR), and whiskers indicate the minimum and maximum observed values. A total of 40 observations from 33 individuals were included in the analysis. (B) Spike-specific antibody titre after 4th and 5th vaccine in matched non-prior infected LTCF residents. Paired T test p = 0.52 n = 11. (C) Spike-specific antibody titre following the fourth and fifth SARS-CoV-2 vaccine doses in prior-infected long-term care facility (LTCF) residents. Antibody responses were analysed using a linear mixed-effects model with participants included as a random effect. Tukey-adjusted pairwise comparisons identified significant differences between Early_4 and Late_5 (p = 0.0242) and between Early_5 and Late_5 (p = 0.0347). However, no significance was observed in the remaining comparisons (Early_4 vs Late_4, p = 0.1838, Early_4 and Early_5, p = 0.6478, Late_4 and Early_5, p = 0.3438, Late_4 and Late_5, p = 0.3086). Data are shown as box-and-whiskers plots, where the centre line represents the median, the box represents the interquartile range (IQR), and whiskers indicate the minimum and maximum observed values. A total of 94 observations from 77 individuals were included in the analysis. (D) Spike-specific antibody titre after 4th and 5th vaccine in matched prior infected LTCF residents. Paired T test p = 0.52, n = 19. (E) Spike-specific antibody titre in relation to days after 4th or 5th vaccine in LTCF residents with no prior infection. Black indicates 4th vaccine (Two-tailed Spearman’s correlation r = −0.404, p = 0.014, n = 36). Grey indicates 5th vaccine (Two-tailed Spearman’s correlation r = −0.139, p = 0.535, n = 22) All fitted lines are linear regressions. (F) Spike-specific antibody titre in relation to days after 4th or 5th vaccine in LTCF residents with prior infection. Red indicates 4th vaccine (Two-tailed Spearman’s correlation r = 0.030, p = 0.779, n = 86). Orange indicates 5th vaccine (Two-tailed Spearman’s correlation r = −0.159, p = 0.294, n = 45). All fitted lines are linear regressions. For analyses that included paired and unpaired data, with more than 3 groups, a linear mixed-effects model was used with participants as a random effect, and then Tukey-adjusted pairwise comparisons were used to correct for multiple testing. Samples assigned to the fourth-dose cohort were collected at significantly different post-vaccination intervals than samples assigned to the fifth-dose cohort (paired Wilcoxon signed-rank test, V = 431.5, p < 0.001). Results Spike-specific antibody responses plateau after 5 vaccines in LTCF residents 309 participants from long-term care facilities (LTCFs) were recruited of which 168 were staff and 141 residents (Table 1). Blood samples were collected after the 3rd, 4th or 5th vaccine. Responses after 5th vaccine in staff members were not assessed as only 3 received the vaccine due to their lower age and clinical risk. 10.1371/journal.pone.0354079.t001Table 1Donor demographics.StaffResidentTotal (%)Total with prior SARS-CoV-2 infection (%) Total vaccine participants 168141309 (100)219 (70) Total 5th vaccine participants 36467 (22)45 (67) Age >=80 2118120 (39)81 (68) Age 65–79 182139 (13)28 (72) Age <= 64 1482150 (48)110 (73) Median age in years (IQR) 51 (40-59)89 (84-93) Female 14196237 (77)168 (71) Male 274572 (23)51 (71) Baseline mRNA vaccine recipients 13168199 (64)137 (69) Baseline ChAdOx1 recipients 3773110 (36)82 (75) Median days between 4th vaccine and sample (IQR) 63 (41-99)133 (106-205) Median days between 5th vaccine and sample (IQR) 30 (26-67)65 (31-104) Total LTCFs 25 Median participants/LTCF (SD) 9 (9.5)(+ indicates SARS-CoV-2 prior infection). Donor demographics. (+ indicates SARS-CoV-2 prior infection). Vaccine dose and prior infection status were then related to SARS-CoV-2 spike-specific antibody response and titres were seen to plateau after the 4th or 5th vaccine, irrespective of prior infection status. Hybrid immunity limited antibody waning after the 4th vaccine but levels stabilised in LTCF residents following 5 vaccines (Fig 1). Of note, the median time between the 4th dose and sampling for residents was 133 days, compared to only 65 days after 5th dose, and so further longer term follow up will be of interest. As such, antibody levels plateau after 5 vaccines and remain broadly stable over the next 100 days irrespective of prior infection status. Bivalent vaccine increases antibody titres against Omicron variants in LTCF residents and enhances neutralisation in infection-naive donors We next determined spike-specific antibody responses against the SARS-CoV-2 Omicron variants BA.1, BA.2, BA.4 and BA.5 in matched samples from elderly LTCF residents following the 4th and 5th (B1 and BA.1 bivalent) vaccine dose. Titres against BA.1 and BA.5 were increased in both groups following bivalent vaccination (Fig 2A). Omicron -specific antibody responses are increased following bivalent vaccination in LTCF residents. A. Ancestral, BA.1, BA.2, BA.4 and BA.5 spike-specific antibody responses after 4th and 5th dose vaccine in non-prior infected LTCF residents. Lines indicate paired samples. Wilcoxon matched-pairs signed rank test; Wuhan p = 0.58, BA.1 p = 0.02, BA.2 p = 0.06, BA.4 p = 0.12, BA.5 p = 0.04, n = 11. B. Ancestral, BA.1, BA.2, BA.4 and BA.5 spike-specific antibody responses after the 4th and 5th dose vaccine in prior infected LTCF residents. Lines indicate paired samples. Wilcoxon matched pairs signed rank test; Wuhan p = 0.3, BA.1 p = 0.03, BA.2 p = 0.0003, BA.4 p = 0.002, BA.5 p = 0.0004, n = 19. Relative viral neutralisation capacity of post-vaccine sera following 4th and 5th vaccines was also assessed [13]. 5th vaccine enhanced BA.1-specific neutralisation in infection-naïve donors (Fig 3A). This trend was also observed in the non-linked data set (S1 Fig). Some increase in neutralisation of the XBB.1.16 and XBB.1.5 variants was seen after both vaccines, most particularly in infection-naive donors with values suggestive of effective neutralisation capacity in vivo. Bivalent vaccine increases BA.1 specific virus neutralisation in LTCF residents. A. Matched antibody neutralisation of ancestral Wuhan, BA.1, XBB.1.16 and XBB1.5 variants from LTCF residents with no prior infection shown after 4th and 5th vaccines. The bottom and top dotted-lined regions indicate weak and complete inhibition, respectively. Wilcoxon matched-pairs signed-rank test; Wuhan p = 0.49, BA.1 = p.027, X.BB.1.1 p = 0.97, XBB.1.5 p = 0.25. B. Matched antibody neutralisation of ancestral Wuhan, BA.1, XBB.1.16 and XBB1.5 variants from LTCF residents with prior infection shown after 4th and 5th vaccines. The bottom and top dotted-lined regions indicate weak and complete inhibition, respectively. Wilcoxon matched-pairs signed-rank test: Wuhan p = 0.44, BA.1 p = 0.13, XBB.1.6 p = 0.622, XBB.1.5 p = 0.51. As such, bivalent vaccine enhances omicron variant-specific antibody titres irrespective of infection status and further enhances neutralisation capacity in donors who remain infection-naive. T cell responses are robust following 5th vaccine with reduced recognition of BA.5 T cell responses against spike protein from ancestral virus and Omicron variants BA.1 and BA.5 were also assessed following the bivalent vaccine (Fig 4A/B). Recognition of ancestral and BA.1 peptides was equivalent whilst those against BA.5 were slightly reduced, irrespective of prior infection status, although sample size was modest in the non-infected group. Robust spike-specific cellular responses in LTCF residents. A. Wuhan, BA.1 or BA.5 spike S1-specific IFN-γ cellular response after bivalent vaccine in prior infected LTCF residents. Black dots represent Wuhan response and green dots represent BA.1 or BA.5 responses. Wilcoxon matched-pairs signed rank test (Wuhan to BA.1 p = 0.33, Wuhan to BA.5 p = 0.02 (n = 16)). B. Wuhan, BA.1 or BA.4/5 spike S1-specific IFN-γ cellular response after bivalent vaccine in non-prior infected LTCF residents. Black represents Wuhan response and Green represents BA.1 or BA.4/5 responses. Wilcoxon matched-pairs signed rank test (Wuhan to BA.1 p = 0.08, Wuhan to BA.5 p = 0.04 (n = 8)). Serial vaccination incrementally supports adaptive immunity protection with additional vaccine doses required for infection-naive donors Antibody and cellular response had been assessed incrementally in LTCF residents and staff within the VIVALDI study since initial vaccination. These prospective findings showed that repeat vaccination had served to deliver robust spike-specific immunity to almost all donors (Fig 5). Humoral and cellular responses following SARS-CoV-2 vaccination during VIVALDI study. (A) Spike-specific antibody or (B) Spike S1 domain cellular responses from all participants in the VIVALDI study during the collection period. Red indicates prior infected donors and black indicates those that remained infection-free. Standard error of the mean (SEM) is shown. The time periods of delivery of the 5 vaccine doses are shown together with times of sample collection. The most dominant SARS-CoV-2 variant that was circulating during sample collection is also represented. SARS-CoV-2 infection status had a substantial impact on early immune profile with prior natural infection serving to stabilise peak antibody profile following primary series vaccination although a 3rd vaccine was required to limit antibody waning. In contrast, 5 vaccines were required to stabilise antibody levels within infection-naive donors. A slightly different profile was seen in relation to cellular responses which were clearly enhanced by primary series vaccination in all donors, required 3 vaccines to reach equity in relation to infection status, and were more stable than humoral immunity. However, this representation is for information only and, as the data have not been tested by statistical analysis, causal dose thresholds and stabilization effects cannot be interpreted. Spearman’s correlation shows that antibody levels in prior infected donors are stable from study onset whilst other measures increase over time: Antibody response PI: r = 0.38 p = 0.12; NPI: r = 0.62 p = 0.005. Spike specific cellular response PI: r = 0.66 p = 0.015 NPI: r = 0.64 p = 0.022. SARS-CoV-2 reinfection is more common in LTCF residents but does not increase spike-specific antibody titre We next assessed prevalence of SARS-CoV-2 infection and reinfection by comparison of nucleocapsid-specific antibody responses in matched participant samples from July 2022 to January 2023 (median interval of 105 days, IQR 99−129 days) when donors had received at least 3 SARS-CoV-2 vaccines. A 2-fold increase in nucleocapsid-specific antibody titre was taken to reflect primary infection or reinfection (S2 Fig) although in the absence of viral screening it was not formally possible to distinquish between new infection, late seroconversion, or potential boosting from recent viral exposure. 16% of staff and 15% of residents developed a primary infection whilst reinfection rates were 13% and 30% respectively. Primary infection boosted spike-specific antibody responses whilst these were not enhanced following reinfection in residents, likely reflecting a ceiling/ plateau effect or stable hybrid immunity, although a modest increase was seen in staff (Fig 6). High rates of primary and secondary SARS-CoV-2 infection within LTCF. A. Nucleocapsid-specific antibody titre from seroconverted staff members. Lines indicate matched samples. Wilcoxon matched-pairs signed rank test. **p = 0.003 n = 9. Spike specific antibody titre. Wilcoxon matched-pairs signed rank test. **p = 0.003 n = 9. B. Nucleocapsid-specific antibody titre from seroconverted residents. Lines indicate matched samples. Wilcoxon matched-pairs signed rank test. *p = 0.032 n = 6. Spike specific antibody titre. Wilcoxon matched-pairs signed rank test. *p = 0.031 n = 6. C. Nucleocapsid-specific antibody titre from reinfected staff. Lines indicate matched samples. Wilcoxon matched-pairs signed rank test. **p = 0.003 n = 9. Spike specific antibody titre. Wilcoxon matched-pairs signed rank test. p = 0.91 n = 9. D. Nucleocapsid-specific antibody titre from reinfected residents. Lines indicate matched samples. Wilcoxon matched-pairs signed rank test. **p = 0.007 n = 8. Spike specific antibody titre. Wilcoxon matched-pairs signed rank test. ** p = 0.007 n = 8. The results indicate continuing high rates of primary and secondary infection within the LTCF environment despite strong spike-specific immunity. Discussion SARS-CoV-2 vaccines provide the cornerstone of clinical protection from Covid-19 and their immunogenicity and clinical utility in the residential care home setting is important to assess. Our findings in this large prospective national study offer confidence that the current regime of serial ancestral and Omicron-specific vaccines elicits robust and stable adaptive immune responses against SAR-CoV-2. Despite this, infection and reinfection rates remain high indicating a potential requirement for adjunctive protective approaches. Spike-specific antibodies are an established correlate of protection and it augurs well that antibody waning was largely overcome following 5th vaccine, as seen in previous reports [14,15]. Longer term follow-up will be required to assess this further [16,17]. Bivalent vaccination also enhanced antibody responses against BA.2 and BA.5 variants, in line within pivotal early studies in older adults [18]. Antibody neutralisation was also markedly increased and supports evidence for the utility of mRNA bivalent products to overcome immune imprinting [19,20]. These incremental responses may underpin the improvement in clinical protection seen from bivalent vaccines in older people within national studies [21]. Cellular immune responses are critical for clinical protection and resilient responses were seen after a 5th vaccine, irrespective of infection status. It is typically reported that cellular responses are largely insensitive to Omicron mutations, and it was therefore interesting to see that recognition of the BA.5 variant was modestly reduced although the small sample size in infection-naive donors limits the precision of these estimates. However, a similar profile has been seen in recipients of solid organ transplants [22] and will require careful monitoring if mutation acquisition were to become concentrated within immunodominant spike peptide epitopes [23]. The fact that we had undertaken long term prospective studies of SARS-CoV-2-specific immunity across the vaccine rollout in the LTCF setting allowed us to undertake a temporal analysis of humoral and cellular responses. A striking feature was the major impact that natural infection had on the magnitude and stability of immune responses. Older residents who survived natural infection have been shown to develop robust virus-specific immunity [10] and hybrid immunity following vaccination was profound. In contrast, infection-naive donors require 5 vaccines to achieve comparable responses. Most people have now had at least one SARS-CoV-2 infection, and this latter group may therefore become largely of historical interest only. The findings demonstrate the rationale for a serial vaccine delivery regime and may underpin the sustained long-term protection against hospitalisation in older people [24]. One of the advantages of our study is that primary series vaccination included both mRNA or adenovirus-based primary regimens and no differences were observed in subsequent response to booster vaccine, in line with data from younger adults [25]. Although vaccines are highly effective in prevention of severe disease and death, they are less effective at preventing re-infection. Indeed, it was notable within this study that although spike-specific immunity was robust after serial vaccination, there was still a 15% primary infection rate during follow up. Re-infection rates were also high at 13% in staff and 30% in residents, although the BA.5 variant was dominant in this period and its effective immune evasion was reflected in national infection prevalence of ~4% per month. It is interesting to reflect on why robust systemic spike-specific adaptive immunity does not provide sterilising immunity against reinfection. Potential factors here could include suboptimal immune protection at mucosal sites, an immune ‘ceiling’ effect that is not able to overcome rapid local increase in viral load, or immune evasion of the BA.5 variant. Nevertheless, this frequency of re-infection in the vulnerable resident population is of concern and has been seen in other settings [26]. This may reflect intrinsic vulnerabilities within the LTCF setting, including close-knit living conditions, shared amenities, and prevalent comorbidities [27]. A limitation of our study is that the clinical significance of these infections and reinfections was not determined. As such, these episodes may be of modest importance if clinically mild. However, as immunity wanes we may start to see reinfections that are associated with severe outcome, hospitalisation or death and it will be important to monitor the incidence and severity of such infections over time. The development of interventions or therapeutic approaches that can reduce reinfection risk could still remain of considerable importance. Potential options here include behavioural approaches such as sanitation or infection isolation, as well as approaches to broaden immune defence through strengthening protection against the spike protein of circulating viral variants or boosting immunity against other viral proteins. Our study has a number of limitations. A significant one is the modest sample size for some analyses and limited pairing of samples across analyses, which reflects limitation in sample size collection from care home residents. These include the lack of routine and case-specific virological testing or information on clinical severity of infection. Demographic information is also limited in relation to determinants such as ethnicity, comorbidities, frailty, or medication use. Further, antibody responses against nucleocapsid are known to wane more rapidly than those against spike protein and, as such, it is conceivable that some donors that were regarded as non-infected had suffered a prior infection. In summary, humoral and cellular spike-specific responses in residents of long-term care facilities plateau after 5 vaccine doses but, despite this, infection and reinfection rates remain high. This indicates an area of residual clinical unmet need which would benefit from additional preventative measures. Supporting information Bivalent vaccine increases BA.1 specific virus neutralisation in LTCF residents but not against current circulating VOCs. A. Antibody neutralisation of ancestral (Wuhan), BA.1 XBB.1.16 and XBB1.15 variants from LTCF residents with no prior infection in relation to time after 4th (6–100 and >100 days) and 5th (6–100 and >100 days) vaccine. Top and bottom dotted lines indicate the continuous region of the data obtained. Between the bottom and one higher region is the weak inhibition region The area between the top two lines is the complete inhibition region. 2 way ANOVA (Tukey’s multiple comparisons test), *p = 0.013, **p = 0.005, n = 40. B. Antibody neutralisation of ancestral (Wuhan), BA.1 XBB.1.16 and XBB1.15 variants from care home residents with prior infection shown in relation to time after 4th (6–100 and >100 days) and 5th (6–100 and >100 days) vaccines. Top and bottom dotted lines indicate the continuous region of the data obtained. Between the bottom and one higher region is the weak inhibition region The area between the top two lines is the complete inhibition region. 2 way ANOVA (Tukey’s multiple comparisons test), *p = 0.013, **p = 0.005, p=<0.0001 n = 92. (DOCX) Anti nucleocapsid and spike specific antibody levels in LTCF residents and staff members that did not change infection status. A. Nucleocapsid specific antibody titre from LTCF residents and staff at two collections. Lines indicate matched samples. Paired T test (Wilcoxon) ****p=<0.0001 n = 64. B. Nucleocapsid specific antibody IgG titre changes between samples collected in July vs Jan between prior infected (PI, red) and non prior infected(NPI, black). n = 64, T-test, ***p = 0.0002. C. Spike specific antibody titre from LTCF residents and staff at two collections. Lines indicate matched samples. Paired T test (Wilcoxon) no statistical difference seen. (DOCX) Transfer Alert This paper was transferred from another journal. As a result, its full editorial history (including decision letters, peer reviews and author responses) may not be present. 21 Oct 2025 30 Dec 2025 Dear Dr. Moss, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Feb 13 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Dhammika Leshan Wannigama, MD PhD Academic Editor PLOS One Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1.Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Thank you for stating the following financial disclosure: “This work was funded by the Department of Health and Social Care (COVID-19 surveillance studies). The work was supported by the Francis Crick Institute which receives its core funding from Cancer Research UK (CC2230, CC2087), the UK Medical Research Council (CC2230, CC2087) and the Wellcome Trust (CC2230, CC2087).” Please state what role the funders took in the study. If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." If this statement is not correct you must amend it as needed. Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf. 3. In the online submission form you indicate that your data is not available for proprietary reasons and have provided a contact point for accessing this data. Please note that your current contact point is a co-author on this manuscript. According to our Data Policy, the contact point must not be an author on the manuscript and must be an institutional contact, ideally not an individual. Please revise your data statement to a non-author institutional point of contact, such as a data access or ethics committee, and send this to us via return email. Please also include contact information for the third party organization, and please include the full citation of where the data can be found. 4. Please amend the manuscript submission data (via Edit Submission) to include author Gokhan Tut,Tara Lancaster, Panagiota Sylla, David Bone, Christopher Bentley, Azar Jadir, Rachel Bruton, Katie Spencer, Soumyajit Mallick, Ahmed Elzaidi, Alexander Dowell,Mary Y Wu, Ruth Harvey, Edward J Carr, Crick COVID Immunity Pipeline, Rupert Beale, Maria Krutikov, Oliver Stirrup, Borscha Azmi, Andrew Hayward, Andrew Copas and Laura Shallcross. 5. Please ensure that you refer to Figure 5 and 6 in your text as, if accepted, production will need this reference to link the reader to the figure. 6. Please remove your figures from within your manuscript file, leaving only the individual TIFF/EPS image files, uploaded separately. These will be automatically included in the reviewers’ PDF. 7. We notice that your supplementary figures are included in the manuscript file. Please remove them and upload them with the file type 'Supporting Information'. Please ensure that each Supporting Information file has a legend listed in the manuscript after the references list. 8. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? Reviewer #1: Yes Reviewer #2: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: Yes Reviewer #2: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes Reviewer #2: No ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #2: Yes ********** Reviewer #1: This manuscript by Tut & Lancaster et al. presents a valuable investigation into the immune response and clinical outcomes following serial SARS-CoV-2 vaccination, including a bivalent booster, in the highly vulnerable nursing home population. The study leverages the VIVALDI cohort to provide longitudinal data on both humoral and cellular immunity. The central finding that robust, plateaued spike-specific immunity does not prevent high rates of reinfection is clinically important. However, I hope the authors would find the comments below helpful in improving the manuscript. Minor The final sentence in the abstract is strong, but the preceding one ("These findings demonstrate...support the value of bivalent vaccines") feels somewhat generic. Consider refining it to more directly reflect the nuanced finding that the vaccine boosts immunity but that this alone is insufficient to prevent infection in this setting. Line 71 and 72 are duplicates (methods) The relationship between the 4th and 5th doses and sample collection needs clarification. Lines 124-127 show a much longer median time between the 4th dose and sampling for residents (133 days) compared to the 5th dose (65 days). This complicates the direct comparison of immune responses between the 4th and 5th doses, as waning may have already occurred for the 4th dose group. This could be acknowledged as a limitation. Clarify the role of staff participants. Their inclusion is appropriate as a comparison group, but the manuscript could explain why only three staff received the 5th dose and how their data were handled. The introduction references “more reassuring outcomes observed in other settings (refs 4,5)” but does not clearly contrast those findings with the current study. There are important variables that are missing or briefly mentioned which greatly influence immune response in this population. While missing variable such as ethnicity, time since prior infection, severity of infections or reinfections were acknowledged, others such as comorbidities, frailty, or medication use need be acknowledged. Major comments - Reinfection is defined solely by a ≥2-fold rise in nucleocapsid IgG. This threshold is not validated, especially in older adults, and natural fluctuations or assay variability could account for such changes. Also, the text acknowledges reduced PCR/LFD testing in later periods, yet the manuscript does not quantify how this limited diagnostic certainty may bias reinfection estimates. Without sequencing or precise timing of infection, it is unclear whether rises in nucleocapsid antibody reflect new infection, late seroconversion, or boosting from recent viral exposure. Authors should justify the two-fold threshold using published references or internal validation. Also consider discussing the risk of misclassification more explicitly. - A major limitation, acknowledged by the authors, is the lack of data on the clinical severity of these primary infections and reinfections. Given that the primary goal of vaccination in this population is to prevent severe disease, hospitalization, and death, the absence of this data significantly weakens the public health message. Were these largely asymptomatic infections detected by routine screening? Or did they lead to hospitalizations? Any available data on symptom severity or healthcare utilization should be included. If no data exists, this key limitation needs to be more explicitly stated. It may be helpful to clarify that reinfection rates may reflect environmental/behavioral exposure rather than vaccine insufficiency. Also, I would avoid implying that reinfections necessarily indicate unmet clinical need unless clinical significance is demonstrated. - The reported 30% reinfection rate in residents over 6 months is presented as "high," which it may well be. However, to properly interpret this, the manuscript needs context. What was the community incidence of SARS-CoV-2 during this specific study period (approx. July 2022 - Jan 2023)? This period likely covered Omicron subvariants like BA.5, which are known for high immune evasion. Stating the dominant variants and community prevalence would help assess whether this 30% rate is truly unexpectedly high given the immune-evasive nature of the circulating viruses and the congregate living setting, or if it is consistent with broader population trends. - The data in Figure 6 and the corresponding text (lines 340-342) are currently confusing. It states that reinfection did not boost spike-specific antibodies in residents "due to high baseline values." However, Figure 6D appears to show a significant increase in spike antibodies in reinfected residents (p=0.007). This direct contradiction between the text and the figure must be resolved. The authors need to clarify their interpretation and ensure the statistical analysis and textual description are aligned. - The discussion focuses on the robustness of the immune response but does not adequately grapple with the core paradox: why do high antibody and T-cell levels not prevent infection? The authors correctly state that vaccines are less effective at preventing infection than severe disease, but they could expatiate further. For instance: Could this be due to differences in mucosal IgA responses, which are critical for blocking infection at the portal of entry? Could the "plateau" of immunity represent a ceiling effect that is still insufficient to neutralize the high viral loads encountered in an LTCF setting? The modest reduction in BA.5-specific T-cell responses is noted, but its potential contribution to breakthrough infections could be discussed more thoroughly. - The suggestion that "further approaches are needed" is appropriate but vague. The discussion could be strengthened by proposing specific "adjunctive protective approaches" (line 369), such as improved ventilation, prophylactic antivirals, or perhaps, next-generation mucosal vaccines. Reviewer #2: The authours have evaluated Older adult residents of long-term care facilities, and their infection/reinfection rates with Sara-CoV-2. While the maunscript is generally acceptable for publication and the data and conculsions are justified. I have some questions that may be considered. The manuscript puts a large amount of emphesis on the 4th to 5th vacine dose "Here we determined humoral and cellular immunity following delivery of a 5th vaccine dose" however Table 2 tells us that only 3 staff (of 168) and 64 residents (of 141) recived the 5th dose. in total only 22% of those in the study. Is it therefore correct to put such emphesis on the 4th to 5th vaccine dose when only 67 people of the 309 in the study actually recived this dose?. Also the inclusion of the Staff - who are a wholely different demographic - mostly much much younger than the residents - this also seems like an odd sub set to be included in the study - which doesnt really get an explanation. The manuscript could also do with a quick grammar check. ********** what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: Yes: Oladayo A. Oyebanji Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. 24 Mar 2026 PONE-D-25-51786 High rates of SARS-CoV-2 reinfection in residents of long term care facilities despite robust spike-specific immunity following serial vaccination. Response to Reviewers We thank the reviewer for their very positive and incisive assessment of our manuscript. We make details comments to each point below. Reviewer #1: This manuscript by Tut & Lancaster et al. presents a valuable investigation into the immune response and clinical outcomes following serial SARS-CoV-2 vaccination, including a bivalent booster, in the highly vulnerable nursing home population. The study leverages the VIVALDI cohort to provide longitudinal data on both humoral and cellular immunity. The central finding that robust, plateaued spike-specific immunity does not prevent high rates of reinfection is clinically important. However, I hope the authors would find the comments below helpful in improving the manuscript. We thank the Reviewer for these positive and helpful comments. Minor The final sentence in the abstract is strong, but the preceding one ("These findings demonstrate...support the value of bivalent vaccines") feels somewhat generic. Consider refining it to more directly reflect the nuanced finding that the vaccine boosts immunity but that this alone is insufficient to prevent infection in this setting. Thank you. This has now been done. Line 71 and 72 are duplicates (methods) We apologise this has been corrected. The relationship between the 4th and 5th doses and sample collection needs clarification. Lines 124-127 show a much longer median time between the 4th dose and sampling for residents (133 days) compared to the 5th dose (65 days). This complicates the direct comparison of immune responses between the 4th and 5th doses, as waning may have already occurred for the 4th dose group. This could be acknowledged as a limitation. Thank you. This has now been listed as a limitation and is discussed in the results section. Clarify the role of staff participants. Their inclusion is appropriate as a comparison group, but the manuscript could explain why only three staff received the 5th dose and how their data were handled. This is a very reasonable point and is now explicitly addressed in the results section The introduction references “more reassuring outcomes observed in other settings (refs 4,5)” but does not clearly contrast those findings with the current study. We apologise for this and these manuscripts have now been described more fully in the Introduction. There are important variables that are missing or briefly mentioned which greatly influence immune response in this population. While missing variable such as ethnicity, time since prior infection, severity of infections or reinfections were acknowledged, others such as comorbidities, frailty, or medication use need be acknowledged. Thank you for identifying this limitation which has now been discussed. Major comments - Reinfection is defined solely by a ≥2-fold rise in nucleocapsid IgG. This threshold is not validated, especially in older adults, and natural fluctuations or assay variability could account for such changes. Also, the text acknowledges reduced PCR/LFD testing in later periods, yet the manuscript does not quantify how this limited diagnostic certainty may bias reinfection estimates. Without sequencing or precise timing of infection, it is unclear whether rises in nucleocapsid antibody reflect new infection, late seroconversion, or boosting from recent viral exposure. Authors should justify the two-fold threshold using published references or internal validation. Also consider discussing the risk of misclassification more explicitly. Thank you for this important point. We agree that in the absence of routine PCR/LFD testing it can be challenging to define coronavirus reinfection and serological assessment must be performed. We utilised a ≥2-fold rise in nucleocapsid IgG as we utilise the MSD platform for antibody measurement and this gives accurate quantification, considerably better than ELISA assays, and we have previously found this of value (PMID: 37391077). Nucleocapsid-specific titres are also notable for waning, with typical t1/2 of 3-6 months, and so any increase above baseline value is highly suggestive of repeat antigen exposure. Nevertheless, the reviewer is entirely correct that this was not validated in this cohort and it is not possible to distinquish between new infection, late seroconversion, or boosting from recent viral exposure. As such, this has now been fully discussed in the Results and Discussion section. - A major limitation, acknowledged by the authors, is the lack of data on the clinical severity of these primary infections and reinfections. Given that the primary goal of vaccination in this population is to prevent severe disease, hospitalization, and death, the absence of this data significantly weakens the public health message. Were these largely asymptomatic infections detected by routine screening? Or did they lead to hospitalizations? Any available data on symptom severity or healthcare utilization should be included. If no data exists, this key limitation needs to be more explicitly stated. It may be helpful to clarify that reinfection rates may reflect environmental/behavioral exposure rather than vaccine insufficiency. Also, I would avoid implying that reinfections necessarily indicate unmet clinical need unless clinical significance is demonstrated. This is a very important point and we appreciate that the clinical severity of SARS-CoV-2 reinfection is likely to decrease over time due to accumulation of protective immunity. We have now added text to further discuss this and to bring out the fact that the clinical importance of approaches that reduce reinfection rates must be constantly reassessed and related to populations at particular risk. - The reported 30% reinfection rate in residents over 6 months is presented as "high," which it may well be. However, to properly interpret this, the manuscript needs context. What was the community incidence of SARS-CoV-2 during this specific study period (approx. July 2022 - Jan 2023)? This period likely covered Omicron subvariants like BA.5, which are known for high immune evasion. Stating the dominant variants and community prevalence would help assess whether this 30% rate is truly unexpectedly high given the immune-evasive nature of the circulating viruses and the congregate living setting, or if it is consistent with broader population trends. We agree that the use of the word ‘high’ is somewhat subjective. We have now included the important information that BA.5 was highly infectious and background national prevalence was high - The data in Figure 6 and the corresponding text (lines 340-342) are currently confusing. It states that reinfection did not boost spike-specific antibodies in residents "due to high baseline values." However, Figure 6D appears to show a significant increase in spike antibodies in reinfected residents (p=0.007). This direct contradiction between the text and the figure must be resolved. The authors need to clarify their interpretation and ensure the statistical analysis and textual description are aligned. Thank you for this. In fact, the antibody increase after reinfection in residents is seen only in the nucleocapsid-specific response. However, there is a statistical increase in spike-specific titre in staff and this has been added to the text. We apologise for the confusion. - The discussion focuses on the robustness of the immune response but does not adequately grapple with the core paradox: why do high antibody and T-cell levels not prevent infection? The authors correctly state that vaccines are less effective at preventing infection than severe disease, but they could expatiate further. For instance: Could this be due to differences in mucosal IgA responses, which are critical for blocking infection at the portal of entry? Could the "plateau" of immunity represent a ceiling effect that is still insufficient to neutralize the high viral loads encountered in an LTCF setting? The modest reduction in BA.5-specific T-cell responses is noted, but its potential contribution to breakthrough infections could be discussed more thoroughly. These are wise points and we have added this discussion to the text. - The suggestion that "further approaches are needed" is appropriate but vague. The discussion could be strengthened by proposing specific "adjunctive protective approaches" (line 369), such as improved ventilation, prophylactic antivirals, or perhaps, next-generation mucosal vaccines. Thank you. We have now added this information. Reviewer #2: The authours have evaluated Older adult residents of long-term care facilities, and their infection/reinfection rates with Sara-CoV-2. While the maunscript is generally acceptable for publication and the data and conculsions are justified. I have some questions that may be considered. Thank you for this assessment. The manuscript puts a large amount of emphesis on the 4th to 5th vacine dose "Here we determined humoral and cellular immunity following delivery of a 5th vaccine dose" however Table 2 tells us that only 3 staff (of 168) and 64 residents (of 141) recived the 5th dose. in total only 22% of those in the study. Is it therefore correct to put such emphesis on the 4th to 5th vaccine dose when only 67 people of the 309 in the study actually recived this dose?. Also the inclusion of the Staff - who are a wholely different demographic - mostly much much younger than the residents - this also seems like an odd sub set to be included in the study - which doesnt really get an explanation. Thank you. Very few staff received a 5th vaccine as they were generally much younger and were therefore not in the demographic group to receive additional booster vaccines. We have now discussed this limitation in the text. The manuscript could also do with a quick grammar check. Thank you. We have now reviewed the complete text and make it more accessible to readers. Submitted filename: Response to Reviewers.docx 6 May 2026 Dear Dr. Moss, Statistical interpretations raised by reviewer need careful consideration while revising the manuscript. Statistical interpretations raised by reviewer need careful consideration while revising the manuscript. plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Mohammad Rashidul Hashan, M.B.B.S.;Ph.D Academic Editor PLOS One Journal Requirements: If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author Reviewer #1: All comments have been addressed Reviewer #3: (No Response) ********** 2. Is the manuscript technically sound, and do the data support the conclusions??> Reviewer #1: Yes Reviewer #3: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: Yes Reviewer #3: No ********** 4. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: (No Response) Reviewer #3: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #3: Yes ********** Reviewer #1: (No Response) Reviewer #3: The aim of this study was to 1. Determine the antibody and cellular immune responses against SARS-CoV-2 following bivalent vaccination in long-term care facilities for older adults, and to 2. Assess breakthrough infection rates. The study uses a subset of VIVALDI cohort to compare immune responses after later booster doses (4th and 5th) to conclude that while the vaccines elicit robust systemic spike-specific immune responses, it does not prevent reinfection. The manuscript addresses an epidemiologically important question and has important public health implications for vulnerable older populations. However, the authors should consider these revisions to allow accurate interpretation of the data. • It is unclear which participants were included in the analyses and in each figure. While the table nicely breaks down the population in the study, it doesn’t provide information about which samples actually ended up in the analyses and the breakdown of staff vs residents. For example, Figure 1A reports an n=41, are these all residents? Are these completely independent samples? Or are there repeated participants in each group? Similarly, Figures 4 and 6 have a different sample size compared to other figures with matched data. The manuscript can really benefit from mapping the included participants/samples into a CONSORT-style diagram and from noting when certain samples are omitted from analysis in specific figures. The sample sizes in matched data are very small. Why? • Statistical analyses in all figures need reconsideration. In figure 1A and C, it is not clear if the analysis included repeated participants (i.e. same people contributed a sample after the 4th dose and after 5th dose). If participants are repeated, then the 4 groups are not fully independent so Kruskal–Wallis test is not appropriate, and a mixed-effects model should be used. • In panels B and D, it would be nice to see a correlation graph between antibody titer after 4th and 5th dose instead of showing only matched data. Also, when were these matched samples collected for the 4th and 5th dose? Are equivalent time points being compared? • 6–100 days is a very wide window. Immune responses at one week and at 3 months are not biologically equivalent, and you lose a lot of information. I suggest further stratifying the groups. • Figure 2: Why were the Wuhan titers for prior infection samples analyzed with paired t test and the rest of the titers analyzed with Wilcoxon matched-pairs signed rank test? Were multiple comparisons done and corrected? Or were these unadjusted comparisons? The authors need to reanalyze and draw conclusions accordingly. From the current p values, bivalent vaccination broadened Omicron spike-binding responses more consistently in prior-infected than in infection-naïve participants. Also, similar to Figure 1, it should be stated whether the paired samples were taken at comparable times after each dose. • Figure 3: again, statistical analysis. Were multiple comparisons done? What were the p values for each variant? How were the thresholds for weak and complete inhibition determined? Or are these the limits of detection of the assay? How did the authors reach the conclusion “bivalent vaccine enhances omicron variant-specific antibody titres irrespective of infection status and further enhances neutralisation capacity in donors who remain infection-naive”? • Figure 4: The manuscript concludes that “Recognition of ancestral and BA.1 peptides was equivalent whilst those against BA.5 were slightly reduced, irrespective of prior infection status”. While cellular responses to BA.5 were modestly reduced in both prior-infected and infection-naive residents, the small sample size in infection-naive donors limits the precision of these estimates. Therefore, conclusions should be framed cautiously. • Figure 5 is informative, but authors should be cautious about overstatements and implying causal dose thresholds and stabilization effects that are not directly tested by the statistical analysis presented. To evaluate changes in immune responses across doses and infection status groups, a mixed-effects longitudinal model would be more appropriate. Additionally, if this data is from all participants in the VIVALDI study, does that mean all ages are included? • Figure 6: How many doses of vaccine did the participants in this figure have at that point? While Primary infection and reinfection events occurred, it is unclear how it was determined that the primary infection participants had “strong immunity”. Some of these participants were sitting at 10–100 BAU/mL in July, that is a low binding-antibody level. The data suggest that a subset of older donors remained weak humoral responders or had substantial waning in July, but with infection, immune responses were boosted. Overall, immunity in this cohort was shaped by both vaccination and repeated infection. In the resident reinfection group, infection did not result in further measurable boosting of spike antibody levels, likely reflecting a ceiling/ plateau effect or stable hybrid immunity. Minor concerns: • In addition to the absence of viral screening and inability to tell the time of prior infection with the use of anti-N IgG, it would strengthen the manuscript to acknowledge that anti-N IgGs decline more rapidly than spike antibodies, especially in older adults. Therefore, there could be some misclassification in the “naive group”. • Additional clarification and description of the analytic structure and interpretation of results in the Results section would substantially improve readability and reduce ambiguity. • Line 343, the text says August 2022 but the figure says July. Make sure it is consistent. ********** what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: Yes: Oladayo A. Oyebanji Reviewer #3: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. 27 Jun 2026 PONE-D-25-51786 Second response to Reviewers Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed Reviewer #3: (No Response) 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #3: Yes 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #3: No 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: (No Response) Reviewer #3: Yes 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #3: Yes 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: (No Response) Reviewer #3: The aim of this study was to 1. Determine the antibody and cellular immune responses against SARS-CoV-2 following bivalent vaccination in long-term care facilities for older adults, and to 2. Assess breakthrough infection rates. The study uses a subset of VIVALDI cohort to compare immune responses after later booster doses (4th and 5th) to conclude that while the vaccines elicit robust systemic spike-specific immune responses, it does not prevent reinfection. The manuscript addresses an epidemiologically important question and has important public health implications for vulnerable older populations. However, the authors should consider these revisions to allow accurate interpretation of the data. Thank you for advising on these potential revisions. We have undertaken these and have made substantial statistical revisions throughout the paper. These have further improved the manuscript and we thank the reviewer for the advice. • It is unclear which participants were included in the analyses and in each figure. While the table nicely breaks down the population in the study, it doesn’t provide information about which samples actually ended up in the analyses and the breakdown of staff vs residents. For example, Figure 1A reports an n=41, are these all residents? Are these completely independent samples? Or are there repeated participants in each group? Similarly, Figures 4 and 6 have a different sample size compared to other figures with matched data. The manuscript can really benefit from mapping the included participants/samples into a CONSORT-style diagram and from noting when certain samples are omitted from analysis in specific figures. The sample sizes in matched data are very small. Why? Thank you for this. The study was undertaken using small sample collections from frail residents in care homes and sometimes not enough cells or plasma was available for study. Laboratory analysis was also undertaken on two sites to maximise expertise. However, we have now made the limitation on sample size and pairing the major focus in our section on the limitations of the study in the Discussion section. • Statistical analyses in all figures need reconsideration. In figure 1A and C, it is not clear if the analysis included repeated participants (i.e. same people contributed a sample after the 4th dose and after 5th dose). If participants are repeated, then the 4 groups are not fully independent so Kruskal–Wallis test is not appropriate, and a mixed-effects model should be used. Thank you for this valuable advice. A mixed effects model has been applied to Figures 1A and 1C. A new figure has been replaced in this regard. The figure legends have been amended appropriately. This analysis removes a prior statistical difference between the groups. However, the PI model showed that the Spike over time was significantly different with a statistical significance in early 4th and later 5th and early 5th and late 5th groups. • In panels B and D, it would be nice to see a correlation graph between antibody titer after 4th and 5th dose instead of showing only matched data. Also, when were these matched samples collected for the 4th and 5th dose? Are equivalent time points being compared? • 6–100 days is a very wide window. Immune responses at one week and at 3 months are not biologically equivalent, and you lose a lot of information. I suggest further stratifying the groups. Thank you for this advice. It is indeed a wide window and this has been added to the limitations of the manuscript. • Figure 2: Why were the Wuhan titers for prior infection samples analyzed with paired t test and the rest of the titers analyzed with Wilcoxon matched-pairs signed rank test? Were multiple comparisons done and corrected? Or were these unadjusted comparisons? The authors need to reanalyze and draw conclusions accordingly. From the current p values, bivalent vaccination broadened Omicron spike-binding responses more consistently in prior-infected than in infection-naïve participants. Also, similar to Figure 1, it should be stated whether the paired samples were taken at comparable times after each dose. Thank you for this. Wilcoxon matched-pairs has been performed on the figure. Comparisons were restricted to five pre-specified SARS-CoV-2 variants selected a priori for their biological relevance. These analyses were hypothesis-driven rather than exploratory, with each comparison addressing a predefined research question rather than representing a broad, data-driven search for associations. Consequently, we did not apply a multiple-testing correction, as our understanding is that such adjustments are generally intended to control the false-positive rate in exploratory analyses involving large numbers of simultaneous comparisons and may be unnecessarily conservative for such a small set of pre-specified hypotheses. • Figure 3: again, statistical analysis. Were multiple comparisons done? What were the p values for each variant? How were the thresholds for weak and complete inhibition determined? Or are these the limits of detection of the assay? How did the authors reach the conclusion “bivalent vaccine enhances omicron variant-specific antibody titres irrespective of infection status and further enhances neutralisation capacity in donors who remain infection-naive”? Thank you. Thresholds for weak and complete inhibition were determined by manufacturers’ guidance. Comparisons were restricted to five pre-specified SARS-CoV-2 variants selected a priori for their biological relevance. These analyses were hypothesis-driven rather than exploratory, with each comparison addressing a predefined research question rather than representing a broad, data-driven search for associations. Consequently, we did not apply a multiple-testing correction, as such adjustments are generally intended to control the false-positive rate in exploratory analyses involving large numbers of simultaneous comparisons and may be unnecessarily conservative for such a small set of pre-specified hypotheses. Wilcoxon matched-pairs has now been performed on the figure • Figure 4: The manuscript concludes that “Recognition of ancestral and BA.1 peptides was equivalent whilst those against BA.5 were slightly reduced, irrespective of prior infection status”. While cellular responses to BA.5 were modestly reduced in both prior-infected and infection-naive residents, the small sample size in infection-naive donors limits the precision of these estimates. Therefore, conclusions should be framed cautiously. Thank you for spotting this. We agree that we over interpreted this effect. This has been rewritten accordingly. • Figure 5 is informative, but authors should be cautious about overstatements and implying causal dose thresholds and stabilization effects that are not directly tested by the statistical analysis presented. To evaluate changes in immune responses across doses and infection status groups, a mixed-effects longitudinal model would be more appropriate. Additionally, if this data is from all participants in the VIVALDI study, does that mean all ages are included? Thank you. We have now amended the text to say that. “However, this representation is for information only and, as the data have not been tested by statistical analysis, causal dose thresholds and stabilization effects cannot be interpreted”. • Figure 6: How many doses of vaccine did the participants in this figure have at that point? While Primary infection and reinfection events occurred, it is unclear how it was determined that the primary infection participants had “strong immunity”. Some of these participants were sitting at 10–100 BAU/mL in July, that is a low binding-antibody level. The data suggest that a subset of older donors remained weak humoral responders or had substantial waning in July, but with infection, immune responses were boosted. Overall, immunity in this cohort was shaped by both vaccination and repeated infection. In the resident reinfection group, infection did not result in further measurable boosting of spike antibody levels, likely reflecting a ceiling/ plateau effect or stable hybrid immunity. Thank you. Recipients had received at least 3 vaccines. We have rewritten this section based on the reviewers comments. Minor concerns: • In addition to the absence of viral screening and inability to tell the time of prior infection with the use of anti-N IgG, it would strengthen the manuscript to acknowledge that anti-N IgGs decline more rapidly than spike antibodies, especially in older adults. Therefore, there could be some misclassification in the “naive group”. Thank you. This is an important point and this has been more clearly stated in the limitations section. • Additional clarification and description of the analytic structure and interpretation of results in the Results section would substantially improve readability and reduce ambiguity. Thank you. This has been added to the Methods section. • Line 343, the text says August 2022 but the figure says July. Make sure it is consistent. We apologise for this error which has been corrected. Submitted filename: Response_to_Reviewers_auresp_2.docx 2 Jul 2026 High rates of SARS-CoV-2 reinfection in residents of long term care facilities despite robust spike-specific immunity following serial vaccination PONE-D-25-51786R2 Dear Dr. Paul, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Mohammad Rashidul Hashan, M.B.B.S.;Ph.D Academic Editor PLOS One Additional Editor Comments (optional): Reviewers' comments: PONE-D-25-51786R2 PLOS One Dear Dr. Moss, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Mohammad Rashidul Hashan Academic Editor PLOS One